ADVANCED BREAST CANCER

This early-stage study tests a new oral medication, PF-08032562, in people with advanced breast or colorectal cancer that has spread. The goal is to find the safest dose and see if it works alone or with other cancer treatments. About 260 adults will take the pill daily in 28-day…

This phase 3 study tests whether adding capivasertib to standard hormone therapy helps people with HR+/HER2- advanced breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib plu…

This early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer or other solid tumors that have spread. The study aims to find the safest an…

This study tests whether adding a trastuzumab biosimilar (SB3) to the chemotherapy drug eribulin helps control advanced HER2-positive breast cancer better than eribulin alone. It is for people whose cancer has returned or spread and who have already tried at least two prior HER2-…

This study tests whether certain drug combinations can help people with advanced ER+ breast cancer whose cancer has stopped responding to common treatments like palbociclib. About 135 participants will receive a treatment chosen based on their tumor's genetic makeup. The goal is …

This study tests two experimental drugs, MHB036C and MHB039A, given together to people with advanced breast cancer or other advanced solid tumors that have spread. The goal is to see if the combination can shrink tumors and how safe it is. About 210 adults aged 18 to 75 with meas…

This study tests an experimental drug called patritumab deruxtecan in people with advanced breast cancer that is hormone-receptor positive but no longer responds to hormone therapy or CDK4/6 inhibitors. About 139 participants will receive the drug every three weeks to see if it s…

This study tests whether adding everolimus to elacestrant can help people with a certain type of advanced breast cancer (ER+/HER2-, with an ESR1 mutation) live longer without their cancer growing. About 240 adults whose cancer has worsened after standard treatments will receive e…

This study compares taking pyrotinib every day versus taking it on a schedule with breaks for people with advanced HER2-positive breast cancer. About 186 adults whose cancer has spread or cannot be removed by surgery will participate. The goal is to see which approach works bette…

This early-stage study tests a new drug called BMS-986500 in people with advanced solid tumors or breast cancer that has stopped responding to standard treatments. The goal is to see if the drug is safe and how the body processes it. About 234 adults will take part, receiving the…

This study tests a new drug called OP-1250 (palazestrant) against standard treatments (fulvestrant or an aromatase inhibitor) in 510 people with a common type of advanced breast cancer (ER+, HER2-). Participants must have already tried hormone therapy plus a CDK4/6 inhibitor. The…

This study tests a new drug called QL1706 in people with a certain type of advanced breast cancer (HR+/HER2-). The goal is to see if it can help keep the cancer from growing longer than standard treatments. About 123 women will take part, and researchers will also monitor for sid…

This early-phase study tests a new drug called BBO-10203 in about 392 adults with advanced solid tumors (like breast, lung, or colorectal cancer) that have not responded to other treatments. The drug works by blocking a key cancer growth pathway. The main goals are to find the sa…

This early-phase study tests an experimental oral drug called BBI-940 in people with advanced or metastatic breast cancer. The drug works by breaking down a protein that cancer cells need to grow. The study will find the safest dose and see if it works alone or with another drug.…

This early-stage study tests a new drug, RLY-2608, designed to target a specific genetic mutation (PIK3CA) found in some advanced solid tumors and breast cancers. The trial will enroll about 930 adults whose cancer has not responded to other treatments. Researchers aim to find th…

This study tests whether a new drug, RLY-2608, combined with fulvestrant works better than another drug combo (capivasertib + fulvestrant) for people with a specific genetic mutation (PIK3CA) in advanced hormone-receptor-positive, HER2-negative breast cancer. About 540 adults who…

This study tests a drug called toripalimab (an immunotherapy) combined with chemotherapy in people with advanced HER2-negative breast cancer that has come back or spread. The goal is to see if the combination can shrink tumors or slow the disease. About 92 adults whose cancer did…

This study tests a single shot of ZOLADEX 10.8 mg to temporarily stop ovarian function in premenopausal women with advanced hormone-positive breast cancer. The goal is to see if the shot can lower certain hormones and stop periods. About 88 women aged 18 to 55 will take part.

This study tests a targeted drug, trastuzumab deruxtecan (T-DXd), against the usual treatment (a CDK4/6 inhibitor plus hormone therapy) for people with a specific type of advanced breast cancer. The cancer must be hormone receptor-positive, HER2-low or ultralow, and have a non-lu…

This early-stage study tests a treatment called TIL therapy for people with advanced breast cancer who have run out of standard options. Doctors take immune cells from a patient's tumor, grow them in a lab, and give them back after a short chemotherapy. The goal is to see if this…

This study tests a new drug called MEN2312 for people with advanced breast cancer that cannot be cured. The drug works by blocking a protein (KAT6) that helps cancer grow. The study will find the safest dose and see if it shrinks tumors or slows the disease. About 240 adults will…

This early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check safety, find the right dose, and see if the dr…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing further. The study includes adults with pancreatic, breast, or other solid t…

This phase 3 study tests whether a new drug combination (saruparib plus camizestrant) works better than current standard treatments for advanced breast cancer that is hormone receptor positive and HER2-negative. The study is for people with BRCA1, BRCA2, or PALB2 gene mutations. …

This study looks at how well and how safely the drug dalpiciclib works for people with a certain type of advanced breast cancer (HR+/HER2-). About 103 participants will take the drug, and researchers will track how long the cancer stays under control and any side effects. The goa…

This study tests a new drug, ETX-636, for people with advanced solid tumors (like breast cancer) that have a specific genetic change called PIK3CA. The drug is designed to block a faulty protein that helps cancer grow. The trial will first test the drug alone, then in combination…

This study tests a two-step treatment plan for 45 women with a certain type of advanced breast cancer (HR+/HER2-low). First, they receive a targeted drug called trastuzumab rezetecan for several months. Then, they switch to a combination of a CDK4/6 inhibitor and hormone therapy.…

This study tests a combination of two drugs—disitamab vedotin and tucatinib—for people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo is safe and can shrink or control tumors. About 172 adults with these cancers who have a…

This study is testing a drug called trastuzumab deruxtecan in 118 adults with advanced breast cancer. The goal is to see how long the drug can keep the cancer from growing and to check for side effects. Participants will receive the drug as part of their normal care, and the stud…

This study tests a drug called Disitamab vedotin in 36 women with advanced breast cancer that has low HER2 levels and has spread. Participants have had only one previous chemotherapy and no prior antibody-drug treatments. The goal is to see if the drug can shrink tumors and contr…

This study looks at whether giving antibody-drug conjugates (ADCs) a second time is safe and effective for people with advanced breast cancer that has spread. About 160 adults who have already received ADCs will be enrolled. The goal is to see if the tumors shrink or stop growing…

This study tests whether the drug sacituzumab govitecan (SG) can still shrink tumors in people with a certain type of advanced breast cancer (HR+/HER2 low) who have already received a similar drug called T-DXd. About 75 adults will receive SG at its standard dose. The goal is to …

This study compares a combination of two chemotherapy drugs (capecitabine and cyclophosphamide) against the doctor's choice of treatment as maintenance therapy for people with advanced breast cancer whose disease is currently under control. The goal is to see if the drug combo ca…

This study tests a telehealth program called ENGAGE for people with stage IV breast, prostate, lung, or colorectal cancer. The program helps manage symptoms like pain, fatigue, and distress that interfere with daily life. About 190 participants will be randomly assigned to ENGAGE…

This study tests whether a digital health platform, which includes a symptom-tracking app and a structured telenursing program, can help cancer patients better manage chemotherapy side effects and improve their quality of life. About 414 adults with early or advanced gastric, lun…

This study enrolls 400 adults with advanced breast, stomach, bladder, or lung cancer who are receiving a type of targeted therapy called an antibody-drug conjugate (ADC). Researchers will compare tumor samples taken before and after treatment to identify genetic or molecular chan…

This study explores how regular video or phone check-ins between patients with advanced breast cancer, their caregivers, and their oncology team can improve the hospice experience at home. Researchers will enroll 200 participants in Massachusetts to see if this approach is practi…